Commodities-focused trading firm Block Commodities is planning to increase value in African agriculture through the use of blockchain. The company, which recently appointed Professors Andrew Garner and Justin Stebbing as part of its Scientific Advisory Team (SAT), is looking to discover and unveil lucrative opportunities in the medical cannabis and CBD wellness fields.
The company is working with other partners to establish pilot studies to develop various cannabis compounds that can treat specific conditions.
Professor Stebbing is a Consultant and a Cancer Medicine and Oncology professor at the Imperial College London. His area of speciality is cancer treatment by immunotherapy.
Stebbing, who is a Fellow of the Royal College of Physicians and the Chair of the Irish Cancer Society oversight committee and World Vaccine Congress, is bringing his vast board experience from his regional and international roles in the medical field.
Professor Andrew Garner possesses an enormous amount of research experience at universities in Europe, the UK, the Middle East and the US. Garner has also held senior positions in the National Health Service and the pharmaceutical industry.
As a highly-experienced pharmacologist, Mr Garner will be relied upon for his vast consultancy and research expertise in the medical space.
CBD research and cultivation
Block Commodities’ decision to work with Professors Stebbing and Garner offers greater assurance of the firm’s management commitment to using medical cannabis for specialised treatment and wellness.
The company is positioning itself as the region’s ultimate CBD research and cultivation market leader, and manufacturer of high-quality efficacious products.
The Chief Executive Officer of the commodities trading firm Ian Tordoff said: “Following the Company’s General Meeting on 27 December 2019, the shareholders approved a new investment strategy to operate in the medicinal cannabis, CBD wellness and hemp sectors.”
He expressed his confidence in the new and existing team members, further adding that the professors would help achieve the firm’s ambition of producing quality OTC products.
“I am delighted to welcome Professor Stebbing and Professor Garner to our Scientific Advisory Team to develop and drive Block’s ambitions in these markets. We aim to create OTC products for consumers who want access to the highest quality CBD products appropriate to their circumstances. We are all looking forward to working closely together in the coming months,” CEO Tordoff said.